MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says ...

When your doctor talks to you about your B-cell lymphoma, they'll tell you what type you have. It's an important piece of info to get, because each type of this cancer acts differently and has its ...

Basophils trigger a cytokine cascade that improves antitumor immunity in mice, offering potential targets for cancer ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...